Battle of the PsO Pills: Investigational Icotrokinra Bests Deucravacitinib (Sotyktu, BMS) in Phase 3 Trials
Icotrokinra, an investigational oral interleukin (IL)-23 blocker, bested deucravacitinib (Sotyktu, BMS) in efficacy and safety, according to the first reported head-to-head trials.